Clinical bottom line
Prurigo pigmentosa is a rare, chronic pruritic dermatosis characterized by recurrent, symmetrical erythematous papules and reticulated hyperpigmentation, predominantly affecting the trunk. Emerging systemic treatments targeting pruritus and inflammation show promise but remain largely investigational. Current evidence on systemic therapies is limited, with most data derived from case reports and small series rather than controlled trials. Novel agents such as KPL-716, an anti-pruritic biologic, have demonstrated preliminary safety and tolerability in chronic pruritic conditions, suggesting potential applicability to prurigo pigmentosa. However, robust clinical trials specifically in prurigo pigmentosa are lacking, and local treatments remain the mainstay. Clinicians should consider systemic options cautiously, tailoring therapy to individual patient severity and comorbidities while awaiting stronger evidence.
What the evidence shows
Prurigo pigmentosa was first described in the 1970s and remains a poorly understood entity with a predilection for young adults, often linked to metabolic or dietary triggers such as ketosis (Nishi Nihon Hifuka, 1976). The pathogenesis involves cutaneous neural proliferation and neurogenic inflammation, contributing to intense pruritus (Runne et al., 1977). Histopathology typically reveals superficial perivascular infiltrates with neutrophils and lymphocytes.
Local treatments, including topical corticosteroids and antibiotics, have been reported to improve lesions and pruritus, particularly post-bariatric surgery cases where metabolic shifts may precipitate disease (Almuhaimeed Mezoun et al., 2021). However, these interventions often provide incomplete or temporary relief.
Systemic therapies remain underexplored. KPL-716, a monoclonal antibody targeting the IL-31 receptor A implicated in pruritus pathways, has undergone early-phase evaluation in chronic pruritic diseases, demonstrating favorable safety and some efficacy signals (Kernel Networks Inc., 2019). Although not specific to prurigo pigmentosa, these findings suggest a mechanistic rationale for systemic anti-pruritic biologics in refractory cases.
Case reports from Germany and Japan highlight the clinical heterogeneity and chronicity of prurigo pigmentosa, underscoring the need for individualized management strategies (Arnold et al., 2024; NAKADA et al., 1998). Böhler et al. (2022) described a rare non-associated prurigo pigmentosa case, emphasizing diagnostic challenges and the importance of excluding mimickers.
Caveats and uncertainty
The evidence base for systemic treatments in prurigo pigmentosa is extremely limited and primarily anecdotal or derived from small cohorts. No randomized controlled trials have specifically addressed systemic agents in this condition. The extrapolation of data from other chronic pruritic diseases to prurigo pigmentosa is hypothesis-generating but unproven.
The natural history of prurigo pigmentosa includes spontaneous remission and recurrence, complicating assessment of treatment efficacy. Moreover, the rarity of the disease limits large-scale studies and consensus on standardized outcome measures.
Potential adverse effects of systemic immunomodulators or biologics must be weighed carefully, especially given the typically young and otherwise healthy patient population. Long-term safety data in prurigo pigmentosa are unavailable.
How this may change practice
Clinicians should maintain a high index of suspicion for prurigo pigmentosa in patients presenting with symmetrical, pruritic, reticulated eruptions on the trunk, particularly in the context of metabolic changes or dietary triggers. Diagnosis remains clinical and histopathological.
Local therapies remain first-line, with topical corticosteroids and antibiotics providing symptomatic relief in many cases. For refractory or severe pruritus, emerging systemic options such as IL-31 receptor antagonists warrant consideration within clinical trials or specialist settings.
Awareness of novel systemic agents under investigation may prompt referral to dermatology centers with access to experimental therapies. Until more definitive evidence emerges, systemic treatment should be individualized, balancing potential benefits against risks.
Further research is needed to clarify the pathophysiology, identify biomarkers, and establish evidence-based systemic treatment protocols for prurigo pigmentosa.